Real-World Study Compares Semaglutide and Tirzepatide for Diabetes and Weight Loss

The global prevalence of Type 2 Diabetes (T2D) and obesity continues to rise, driving demand for effective pharmacological interventions. GLP-1 receptor agonists like Semaglutide and the dual GIP/GLP-1 receptor agonist Tirzepatide have revolutionized treatment, demonstrating significant efficacy in glycemic control and weight reduction. However, a critical knowledge gap exists regarding how these two leading medications compare in terms of short-term adverse events, treatment persistence, and real-world efficacy across diverse patient populations.

The study revealed that both Semaglutide and Tirzepatide significantly improved glycemic control and led to substantial weight loss in a real-world setting. Tirzepatide demonstrated superior efficacy in weight reduction, with patients achieving an average 15.2% body weight reduction compared to 10.1% with Semaglutide over 6 months (a 50% greater reduction, p<0.001). Glycated hemoglobin (HbA1c) levels decreased by 2.1% with Tirzepatide versus 1.6% with Semaglutide (both p<0.001). Adverse events, predominantly gastrointestinal, were common in both groups, with Tirzepatide showing a slightly higher rate of discontinuation due to side effects (18.5% vs 14.9% for Semaglutide, p=0.04). Treatment persistence was comparable, with approximately 72% of patients continuing therapy at 6 months for both drugs. > Tirzepatide achieved a 50% greater reduction in body weight and a 31% greater reduction in HbA1c compared to Semaglutide in a real-world setting, establishing its superior short-term metabolic efficacy.